Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

What trends did delegates notice, in terms of new modalities, technologies, and approaches? Precision, personalisation, and ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...